November 19, 2008

HELIX BIOPHARMA PRESENTS PRECLINICAL L-DOS47 DATA AT THE SECOND CONFERENCE OF LUNG CANCER IN WARSAW POLAND (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) today announced that it will present preclinical data about the mechanism of action for L-DOS47, the first drug candidate under development based on the Company’s DOS47 technology, at The Second Conference of Lung Cancer on November 22, 2008, at the Hyatt Regency Hotel in Warsaw, Poland.